Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации10672Conference ProceedingsCytological screening in the Voronezh region: relevance, statistical data, problems and ways of improvementFedotovaEkaterina Igorevnafedotovaekaterina307@mail.ruhttps://orcid.org/0000-0002-2132-9257KorotkikhIrina Nikolaevnakorotkikh_1950@mail.ruhttps://orcid.org/0000-0001-6525-5934KorotkikhNatalia Viktorovnakornat78@mail.ruhttps://orcid.org/0000-0002-0308-513XGlazyevaElena Sergeevnaviktoryrot@yandex.ruVoronezh State Medical University named after N.N. BurdenkoBurdenko Voronezh State Medical University3006202514133370903202509032025Copyright © 2025, Fedotova E.I., Korotkikh I.N., Korotkikh N.V., Glazyeva E.S.2025<p>A steady increase in the incidence of cervical malignancy (cervical cancer) and the rejuvenation of the age group of patients actualize the need to optimize preventive programs and methods of early detection of the disease. Special attention is paid to the annual increase in the number of newly diagnosed pathologies among women of reproductive age (21-35 years). According to the statistics of the Voronezh Region, in 2023, 242 patients with newly diagnosed ZNO were registered, and 50% of them had the disease detected at stage I. This pathology remains a significant factor in female mortality: mortality in the first year after diagnosis reaches 12.7% in the Russian Federation, demonstrating a steady negative trend. The persistence of human papillomavirus (HPV), especially highly oncogenic types (HPV-16 and HPV-18), is recognized as a key factor in the development of breast cancer. Despite the possibility of preventing breast cancer through timely diagnosis of precancerous conditions, the problem is compounded by low coverage of screening programs and insufficient effectiveness of preventive examinations. The article discusses regional statistical data and modern cytological screening strategies, including two-stage diagnosis. An analysis of 3 years of data (270,748 women were examined) revealed an HPV-positive status in 15.63% of the surveyed. Distribution by serotypes: 29.7% types 16/18; 44.4% 2-3 serotypes; 8.4% 4 or more serotypes. These data confirm the importance of HPV screening in the prevention of breast cancer, and combined diagnosis (PAP test and HPV typing) has proven effective in reducing morbidity and mortality. The successful implementation of screening requires the combined efforts of medical professionals, health authorities and the public.</p>cervical cancercytological screeningHPV testingpreventionрак шейки маткицитологический скринингВПЧ-тестированиепрофилактика1.Arbyn M. et al. "HPV-based cervical cancer screening: Guidelines and current evidence" // Lancet Oncology, 2023.2.World Health Organization (WHO). "Cervical cancer." 2023.3.Коротких Н.В., Мошуров И.П., Аржаных А.В., Кузьмин И.Б., Миронова В.А. Вторичная профилактика впч-ассоциированных злокачественных новообразований шейки матки. В сборнике: Вековой юбилей Воронежской онкологической службы. Сборник трудов научно-практической конференции. Воронеж, 2024. С. 22-25.4.Мошуров И.П., Аржаных А.В., Коротких Н.В. Рак шейки матки. Показатели заболеваемости и смертности в Воронежской Области // Онкогинекология. 2023. № 3 (47). С. 45-49.5.Canfell K. et al. "Impact of HPV vaccination on cervical cancer incidence: A global perspective" // Nature Reviews Clinical Oncology, 2024.6.Cuschieri K. et al. "Self-sampling for HPV testing: Expanding access to cervical screening" // International Journal of Cancer, 2023.7.Гатагажева З.М., Узденова З.Х., Зеленова О.В. Социокультурные барьеры в реализации скрининговых программ // Социология медицины. 2019. № 2. С. 67-73.